Blog
RSS FeedPosted by Michael Wonder on 10 Nov 2022
Olaparib for adjuvant treatment of patients with high risk, HER2 negative, BRCA positive early breast cancer after chemotherapy
10 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 08 Nov 2022
NICE final draft guidance adds further treatment option for triple negative breast cancer
8 November 2022 - NICE has today published final draft guidance which recommends pembrolizumab as an option for people with ...
Posted by Michael Wonder on 23 Oct 2022
Could more medicines be recommended for routine commissioning rather than spending time in the Cancer Drugs Fund?
19 October 2022 - A new analysis commissioned by the ABPI suggests they could. ...
Posted by Michael Wonder on 19 Oct 2022
Zanubrutinib for the treatment of patients with Waldenström’s macroglobulinaemia
19 October 2022 - NICE has published evidence-based recommendations on the use of zanubrutinib for the treatment of adults with ...
Posted by Michael Wonder on 19 Oct 2022
Pembrolizumab for adjuvant treatment of adults with renal cell carcinoma
19 October 2022 - NICE has published evidence-based recommendations on the use of pembrolizumab for the adjuvant treatment of adults ...
Posted by Michael Wonder on 12 Oct 2022
Lutetium Lu 177 vipivotide tetraxetan for treating PSMA positive hormone relapsed metastatic prostate cancer after two or more therapies
12 October 2022 - The Department of Health and Social Care has asked the NICE to produce guidance on using ...
Posted by Michael Wonder on 11 Oct 2022
Nivolumab in combination for untreated advanced unresectable recurrent or metastatic oesophageal squamous cell carcinoma
11 October 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 07 Oct 2022
Pembrolizumab in combination with platinum-based chemotherapy for treating recurrent, persistent or metastatic cervical cancer
5 October 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 06 Oct 2022
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
28 September 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 05 Oct 2022
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy
5 October 2022 - NICE has published evidence based recommendations on the use of azacitidine for the maintenance treatment of ...
Posted by Michael Wonder on 28 Sep 2022
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
28 September 2022 - NICE has published evidence-based recommendations on the use of atezolizumab for adjuvant treatment of adults with ...
Posted by Michael Wonder on 23 Sep 2022
1,500 people set to receive new skin cancer treatment that reduces the risk of it returning and spreading
23 September 2022 - Around 1,500 people aged 12 years and over with melanoma are set to benefit from pembrolizumab (also ...
Posted by Michael Wonder on 23 Sep 2022
NICE approves routine use of drug combination for advanced breast cancer
23 September 2022 - Another life-extending drug combination for some people with advanced breast cancer will now be available for routine ...
Posted by Michael Wonder on 20 Sep 2022
NICE recommends BeiGene’s Brukinsa (zanubrutinib) for patients with Waldenström’s macroglobulinaemia who have had at least one treatment
19 September 2022 - Brukinsa Is the first Bruton’s tyrosine kinase inhibitor recommended by NICE for routine use for Waldenström’s macroglobulinaemia. ...
Posted by Michael Wonder on 14 Sep 2022
NICE inks another early full stop on the appraisal of a cancer medicine
14 September 2022 - Once again, the sponsor decided not to provide an evidence submission. ...